Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Apoptosis and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3777
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Apoptosis and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Apoptosis and Peptides.

    To find out more about Triple Analysis: Leukemia, Apoptosis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Apoptosis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
7TM Pharma
Abbott
Abiogen
Acceleron Pharma
Access
Actinium Pharmaceuticals
Advanced Life Sciences
Advaxis
AEgera
AEterna Zentaris
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alexion
Alfa Wassermann
Allostera
Allosterix
Alnylam
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisoma
Aphios
AplaGen Biopharmaceuticals
Apogenix
ApopLogic Pharmaceuticals
Arca biopharma
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Avila Therapeutics
Basilea Pharmaceutica
Baxter International
Bayer
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
BioInvent
Biokine Therapeutics
BioLineRx
Biomas
Bionovo
BioSante
Bioton
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cephalon
ChemoCentryx
Chemokine Therapeutics
Chiasma
Chlorogen
Choongwae
Chroma Therapeutics
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinuvel
CombinatoRx
Compugen
Cornerstone Pharmaceuticals
Coronado Biosciences
Critical Outcome Technologies
CSL
Curacyte
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Digna Biotech
Dong-A
Dongkook Pharm
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Formula Pharmaceuticals
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
GlycoMimetics
Glycotope
GP Pharm
GPC Biotech
Green Cross
Gryphon Therapeutics
Hanmi
Harbor BioSciences
Hayashibara
Heber Biotec
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Johnson & Johnson
KAEL-GemVax
KaloBios
Kalypsys
Kanisa
Karyon-CTT
Keryx Biopharmaceuticals
Kinex
Kirax
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
Marillion Pharmaceuticals
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Memgen
Merck & Co
Merck KGaA
MethylGene
Micromet
MolMed
Mologen
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
NPS Pharmaceuticals
Onconova
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
Otsuka
OXiGENE
PanaGin
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
ProMetic Life Sciences
Protagonist
Q Chip
QLT
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regulon
Reliance Life Sciences
Rigel
Rosetta Genomics
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Sepal Pharma
Serometrix
Servier
Shenogen
Shire
Sidus
Sigma-Tau
Soligenix
Southern Research Institute
Spectrum Pharmaceuticals
Spirogen
SRI International
Stemline Therapeutics
SuperGen
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Tactic Pharma
Takeda
Talon Therapeutics
Targa Therapeutics
TargeGen
Taxolog
TeGenero
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Trion Pharma
UMN Pharma
Unigene
United Biomedical
Valeant
ValiRx
Vaxil BioTherapeutics
Vaxon Biotech
VBL Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viragen
Viralytics
ViroTarg
VM Discovery
XBiotech
Xencor
Xigen
Yamasa Corporation
Zelos Therapeutics
Zensun
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abarelix
ABT-510
AEG-35156
AEZS-108
afamelanotide
alemtuzumab
alvocidib
AME-133
amonafide malate
amsacrine
angiopep+paclitaxel
APG-101
ARQ-197
AS-101
AS-1411
barasertib
bardoxolone methyl
belinostat
bisantrene
bortezomib
bosutinib
BZL-101
canfosfamide hydrochloride
CBP-501
cenersen
cintredekin besudotox
cladribine
clofarabine
conatumumab
corticorelin acetate
crolibulin
CSF-GM
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
decitabine
deslorelin
dinaciclib
dulanermin
E-75
elacytarabine
emepepimut-S
enocitabine
enzastaurin hydrochloride
EP-100
fosbretabulin tromethamine
FPI-01
gataparsen
gemtuzumab ozogamicin
goserelin
GT-111
GV-1001
GX-301
HE-3235
Her-2/Neu peptides
histamine dihydrochloride
histrelin
ibritumomab tiuxetan
idarubicin
idronoxil
imatinib mesilate
imetelstat
imMucin
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
IPP-204106
ISA-P53-01
kahalalide F
lanreotide
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
litronesib
lonaprisan
lumiliximab
mapatumumab
MDX-1379
midostaurin
mitoxantrone
MKC-1
mocetinostat
motexafin gadolinium
NAFB001
navitoclax
netupitant
nilotinib
noscapine
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ofatumumab
ON-01910
Oncohist
OTS-102
ozarelix
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
PBI-1402
PCI-24781
peginterferon alfa-2b
pentostatin
plitidepsin
polyclonal antibody stimulator
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
razoxane
retaspimycin
rhIFN-alpha
rindopepimut
rituximab
romurtide
sagopilone
seliciclib
sobuzoxane
sotatercept
SPC-2996
ß-lapachone
SU-6668
Survivac
tamibarotene
teniposide
terameprocol
thymalfasin
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
TM-30339
triciribine phosphate
TRU-016
vapreotide, immediate-release
vitespen
volasertib
vosaroxin
VX-001
XL-147
XL-647
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Apoptosis and Peptides.
    To find out more about Triple Analysis: Leukemia, Apoptosis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Apoptosis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Angiogenesis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Learn More


Triple Analysis: Breast Cancer, Lung Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lung Cancer and by the compound strategy of Antibodies. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lymphoma, Melanoma and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Lymphoma, Melanoma and Pancreatic Cancer. Learn More


Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others
This report represents a new and unique way of stratifying and analyzing the global breast cancer drug pipeline towards personalized medicine. Learn More